The efficacy and safety of CAR-T cell therapy in patients with refractory ALL and concomitant HBV infection - Lai, Peilong; Chen, Xiaomei; Qin, Le; Jiang, Zhiwu; Luo, Chenwei; Huang, Xin; Wu, Sujing; Ling, Wei; Wang, Yulian; Wang, Jinghua; Deng, Chenxin; Huang, Lisi; et al. (Leukemia, 2020)
Keywords: 14/5; 631/250/251; 64/60; 692/700/565/251; Animals; Cancer Research; Cell therapy; Critical Care Medicine; Development and progression; Disease Models, Animal; Female; Health aspects; Hematology; Hepatitis B; Hepatitis B - complications; Hepatitis B - diagnosis; Hepatitis B - immunology; Hepatitis B - virology; Hepatitis B virus - immunology; Humans; Immunotherapy, Adoptive - adverse effects; Immunotherapy, Adoptive - methods; Intensive; Internal Medicine; Letter; Lymphocytes; Lymphocytes T; Male; Medicine; Medicine & Public Health; Mice; Middle Aged; Oncology; Precursor Cell Lymphoblastic Leukemia-Lymphoma - complications; Precursor Cell Lymphoblastic Leukemia-Lymphoma - diagnosis; Precursor Cell Lymphoblastic Leukemia-Lymphoma - immunology; Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy; Receptors, Antigen, T-Cell; Receptors, Chimeric Antigen; T cells; T-Lymphocytes - immunology; T-Lymphocytes - metabolism; Treatment Outcome; Xenograft Model Antitumor Assays